{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:16:37Z","timestamp":1786115797858,"version":"build-2736575974"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:p>Use of psychedelic substances is increasing across unregulated, state-regulated, research, ceremonial\/religious, and medical settings in the United States. Concurrently, a growing body of clinical research signals the potential for therapeutic applications for specific psychedelics in the treatment of depression, post-traumatic stress disorder, substance use disorders, and other health conditions. This evolving landscape presents both promise and complexity. From a public health perspective, a structured public health preparedness approach is needed to prioritize safety, workforce readiness, and data infrastructure in a manner that promotes individual and collective well-being while supporting responsible evidence development. This commentary proposes priorities for public health preparedness for psychedelics: (1) education and prevention of adverse events; (2) behavioral health workforce development; and (3) strategic information and data analysis. Educational efforts should emphasize clear risk communication, substance-specific messaging, prevention of adverse events, and practical guidance to support policy decision-making. Workforce considerations include defining core competencies, clarifying ethical boundaries and informed consent, establishing training and technical assistance infrastructure, strengthening capacity across the behavioral health workforce, and preparing providers to respond to patients using psychedelics outside regulated systems. Strategic information priorities include strengthening data systems and improving coordination and harmonization of epidemiologic monitoring related to patterns of use, adverse events, treatment-seeking behaviors, and the implications of evolving policy environments. As psychedelics enter mainstream discourse, public health institutions must adopt a balanced approach that considers both benefits and risks. A proactive, health-promoting, and data-driven framework can help ensure that policies and practices are grounded in safety and core public health principles.<\/jats:p>","DOI":"10.3389\/fpubh.2026.1900601","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T05:33:45Z","timestamp":1785994425000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Priorities for public health preparedness for psychedelics: education, workforce readiness, and strategic information needs in a rapidly changing landscape"],"prefix":"10.3389","volume":"14","author":[{"given":"R. Cameron","family":"Wolf","sequence":"first","affiliation":[{"name":"Substance Abuse and Mental Health Services Administration (SAMHSA)","place":["Rockville, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"Lambert","sequence":"additional","affiliation":[{"name":"Substance Abuse and Mental Health Services Administration (SAMHSA)","place":["Rockville, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Shoar","sequence":"additional","affiliation":[{"name":"Substance Abuse and Mental Health Services Administration (SAMHSA)","place":["Rockville, MD, United States"]},{"name":"Keck School of Medicine, University of Southern California","place":["Los Angeles, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua S.","family":"Hunt","sequence":"additional","affiliation":[{"name":"Substance Abuse and Mental Health Services Administration (SAMHSA)","place":["Rockville, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Donato","sequence":"additional","affiliation":[{"name":"Substance Abuse and Mental Health Services Administration (SAMHSA)","place":["Rockville, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Gandotra","sequence":"additional","affiliation":[{"name":"Substance Abuse and Mental Health Services Administration (SAMHSA)","place":["Rockville, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"100454","DOI":"10.1016\/j.abrep.2022.100454","article-title":"Use of plant-based hallucinogens and dissociative agents: U.S. time trends, 2002\u20132019","volume":"16","author":"Walsh","year":"2022","journal-title":"Addict Behav Rep"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.annemergmed.2023.11.003","article-title":"The rise of psychedelic drug use associated with legalization\/decriminalization: an assessment with the nonmedical use of prescription drugs survey","volume":"83","author":"Monte","year":"2024","journal-title":"Ann Emerg Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.7326\/ANNALS-24-03145","article-title":"The rise of psilocybin use in the United States: a multisource observational study","volume":"178","author":"Rockhill","year":"2025","journal-title":"Ann Intern Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1111\/add.16589","article-title":"Commentary on Darke et al.: expanded psychedelic access requires new safety monitoring systems","volume":"119","author":"Korthuis","year":"2024","journal-title":"Addiction"},{"key":"ref5","volume-title":"Key Substance Use and Mental Health Indicators in the United States: Results from the 2024 National Survey on Drug Use and Health","year":"2025"},{"key":"ref6","volume-title":"Monitoring the Future Panel Study Annual Report: National Data on Substance Use among Adults ages 19 to 65, 1976\u20132025","author":"Miech","year":"2025"},{"key":"ref7","volume-title":"Considering Alternatives to Psychedelics: Future Directions for Policy, Research, and Practice","year":"2025"},{"key":"ref8","volume-title":"Oregon Psilocybin Services Act (Ballot Measure 109), Codified at ORS 475A","year":"2020"},{"key":"ref9","volume-title":"Colorado Natural Medicine Health Act of 2022 (Proposition 122), Codified at Colo Rev Stat \u00a7\u00a7 12-170-101-117","year":"2022"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1001\/jamapsychiatry.2022.4101","article-title":"Psychedelic drug legislative reform and legalization in the US","volume":"80","author":"Siegel","year":"2023","journal-title":"JAMA Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1001\/jama.2023.24762","article-title":"State-regulated psychedelics on a collision course with FDA","volume":"330","author":"Marks","year":"2023","journal-title":"JAMA"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J Psychopharmacol"},{"key":"ref16","year":"2026"},{"key":"ref17","year":"2026"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.1186\/s12889-025-25402-4","article-title":"Defining a public health approach to substance use: insights from a systematic scoping review and conceptual framework development approach","volume":"25","author":"Mathias","year":"2025","journal-title":"BMC Public Health"},{"key":"ref19","year":"2024"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/bs.apha.2021.10.003","article-title":"Human behavioral pharmacology of psychedelics","volume":"93","author":"Strickland","year":"2022","journal-title":"Adv Pharmacol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1177\/0269881116662634","article-title":"Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences","volume":"30","author":"Carbonaro","year":"2016","journal-title":"J Psychopharmacol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-9304959\/v1","article-title":"Extended difficulties after psychedelic experiences: prevalence and associations in a global, multilingual sample","author":"Oliver","year":"2026","journal-title":"Res Sq"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1176\/appi.prcp.20240128","article-title":"On minimizing risk and harm in the use of psychedelics","volume":"7","author":"Evans","year":"2025","journal-title":"Psychiatr Res Clin Pract"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jad.2023.01.073","article-title":"Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics","volume":"326","author":"Simonsson","year":"2023","journal-title":"J Affect Disord"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1080\/02791072.2022.2039815","article-title":"Contextual parameters associated with positive and negative mental health in recreational psychedelic users","volume":"55","author":"St Arnaud","year":"2023","journal-title":"J Psychoactive Drugs"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1293243","DOI":"10.3389\/fpsyt.2023.1293243","article-title":"Group psychedelic therapy: empirical estimates of cost-savings and improved access","volume":"14","author":"Marseille","year":"2023","journal-title":"Front Psych"},{"key":"ref27","year":"2026"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1126\/science.adf0435","article-title":"Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors","volume":"379","author":"Vargas","year":"2023","journal-title":"Science"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1176\/appi.ajp.20250110","article-title":"An update on psychotherapy for the treatment of PTSD","volume":"182","author":"Rothbaum","year":"2025","journal-title":"Am J Psychiatry"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"100538","DOI":"10.1016\/j.eclinm.2020.100538","article-title":"Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study","volume":"27","author":"Anderson","year":"2020","journal-title":"EClinicalMedicine"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1176\/appi.ajp.20240751","article-title":"Research and implementation of psychedelic-assisted therapy in the veterans health administration","volume":"182","author":"Wolfgang","year":"2025","journal-title":"Am J Psychiatry"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e102251","DOI":"10.7759\/cureus.102251","article-title":"Ethics of psychedelic-assisted psychotherapy","volume":"18","author":"Abbasian","year":"2026","journal-title":"Cureus"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s12152-026-09645-5","article-title":"Ethical complexities and best practices in informed consent processes for psilocybin services: a qualitative study","volume":"19","author":"Chwyl","year":"2026","journal-title":"Neuroethics"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1900601\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T05:33:47Z","timestamp":1785994427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1900601\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":33,"alternative-id":["10.3389\/fpubh.2026.1900601"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1900601","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"article-number":"1900601"}}